Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

A pilot study for individuals with Type 1 Diabetes who are willing to add an SGLT-2i (Sodium-Glucose Cotransporter-2 Inhibitor) in combination with placebo or a GRA (Glucagon Receptor Antagonist) to their current diabetes treatment regimen. There will be 15 study visits over approximately 14 weeks in this cross-over study design. Treatment \"A\" consists of an SGLT-2i + GRA for 4 weeks and treatment \"B\" consists of an SGLT-2i + placebo for 4 weeks. All participants will complete both treatment \"A\" and treatment \"B\" with a 6-week washout period in between the treatments. Testing includes 3 insulin withdraw challenges, 3 muscle biopsies, 3 fat biopsies, 3 vascular ultrasounds along with blood collection and vitals.